These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9348421)

  • 1. Early detection of Alzheimer disease: methods, markers, and misgivings.
    Green RC; Clarke VC; Thompson NJ; Woodard JL; Letz R
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 5():S1-5; discussion S37-9. PubMed ID: 9348421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attitudes to Alzheimer's disease testing of Australian general practice patients: a cross-sectional questionnaire-based study.
    Magin P; Juratowitch L; Dunbabin J; McElduff P; Goode S; Tapley A; Pond D
    Int J Geriatr Psychiatry; 2016 Apr; 31(4):361-6. PubMed ID: 26258761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.
    Fleisher AS; Sun S; Taylor C; Ward CP; Gamst AC; Petersen RC; Jack CR; Aisen PS; Thal LJ
    Neurology; 2008 Jan; 70(3):191-9. PubMed ID: 18195264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals.
    Berti V; Murray J; Davies M; Spector N; Tsui WH; Li Y; Williams S; Pirraglia E; Vallabhajosula S; McHugh P; Pupi A; de Leon MJ; Mosconi L
    J Nutr Health Aging; 2015 Apr; 19(4):413-23. PubMed ID: 25809805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset.
    Saxton J; Lopez OL; Ratcliff G; Dulberg C; Fried LP; Carlson MC; Newman AB; Kuller L
    Neurology; 2004 Dec; 63(12):2341-7. PubMed ID: 15623697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical presentation of Moroccan cases with Alzheimer's disease].
    El Kadmiri N; Zaid Y; Hamzi K; Nadifi S; Slassi I; El Moutawakil B
    Encephale; 2014 Dec; 40(6):481-6. PubMed ID: 25127896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects.
    Visser PJ; Verhey FR; Scheltens P; Cruts M; Ponds RW; Van Broeckhoven CL; Jolles J
    J Neurol; 2002 Mar; 249(3):312-9. PubMed ID: 11993532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The validation of a mailed health survey for screening of dementia of the Alzheimer's type.
    Ball LJ; Ogden A; Mandi D; Birge SJ
    J Am Geriatr Soc; 2001 Jun; 49(6):798-802. PubMed ID: 11454121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychological Testing in Pathologically Verified Alzheimer Disease and Frontotemporal Dementia: How Well Do the Uniform Data Set Measures Differentiate Between Diseases?
    Ritter AR; Leger GC; Miller JB; Banks SJ
    Alzheimer Dis Assoc Disord; 2017; 31(3):187-191. PubMed ID: 28005562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years.
    Tierney MC; Yao C; Kiss A; McDowell I
    Neurology; 2005 Jun; 64(11):1853-9. PubMed ID: 15955933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
    Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment.
    Tabert MH; Manly JJ; Liu X; Pelton GH; Rosenblum S; Jacobs M; Zamora D; Goodkind M; Bell K; Stern Y; Devanand DP
    Arch Gen Psychiatry; 2006 Aug; 63(8):916-24. PubMed ID: 16894068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CERAD neuropsychological assessment battery total score detects and predicts Alzheimer disease dementia with high diagnostic accuracy.
    Wolfsgruber S; Jessen F; Wiese B; Stein J; Bickel H; Mösch E; Weyerer S; Werle J; Pentzek M; Fuchs A; Köhler M; Bachmann C; Riedel-Heller SG; Scherer M; Maier W; Wagner M;
    Am J Geriatr Psychiatry; 2014 Oct; 22(10):1017-28. PubMed ID: 23759289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychological markers of progression from mild cognitive impairment to Alzheimer's disease.
    Marcos A; Gil P; Barabash A; Rodriguez R; Encinas M; Fernández C; Cabranes JA
    Am J Alzheimers Dis Other Demen; 2006; 21(3):189-96. PubMed ID: 16869340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of Alzheimer's disease: a new working memory paradigm.
    Toepper M; Beblo T; Thomas C; Driessen M
    Int J Geriatr Psychiatry; 2008 Mar; 23(3):272-8. PubMed ID: 17621381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Montreal cognitive assessment: validation study for mild cognitive impairment and Alzheimer disease.
    Freitas S; Simões MR; Alves L; Santana I
    Alzheimer Dis Assoc Disord; 2013; 27(1):37-43. PubMed ID: 22193353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease.
    JAMA; 1995 Nov 22-29; 274(20):1627-9. PubMed ID: 7474250
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.